TQB2101 / Sino Biopharm - LARVOL DELTA

A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Hematological Malignancies • Oncology

VOLUNTARY ANNOUNCEMENT APPLICATION FOR CLINICAL TRIAL OF “TQB2101 (ROR1 ADC)” APPROVED BY NMPA (HKEXnews) - "The board of directors (the 'Board') of Sino Biopharmaceutical Limited (the 'Company', together with its subsidiaries, the 'Group') announces that the Group’s self-developed 'TQB2101 (ROR1 ADC)' has been given implied approval for clinical trial by the National Medical Products Administration (NMPA) of China. The drug is intended for use in the treatment of advanced malignant tumours....The approved Phase I clinical trial will focus on evaluating its safety, tolerability, pharmacokinetics and preliminary efficacy in humans."

New P1 trial • Solid Tumor

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Breast Cancer • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor